Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Q-linea AB ( (SE:QLINEA) ) has shared an update.
Q-linea AB has achieved its first clinical implementations of the ASTar rapid antibiotic susceptibility testing system in the United States, with University of Iowa Health Care and a major Texas healthcare system now using the instrument. At UI Health Care, ASTar will expand statewide blood culture testing capacity, enabling faster selection of effective antibiotics for septic and other critically ill patients, and is expected to improve outcomes, reduce time to optimal therapy and streamline laboratory workflows through features such as full automation, high-throughput random-access testing, broad antibiotic panels and direct integration with Epic’s electronic medical record system, strengthening Q-linea’s foothold in the US hospital market for rapid AST solutions.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Swedish medtech company specialising in rapid antibiotic susceptibility testing (AST) for bloodstream infections and sepsis. Its flagship product, the fully automated ASTar system, is designed to shorten time to optimal antimicrobial therapy, helping hospitals improve outcomes for critically ill patients and support more sustainable antibiotic use. Headquartered in Uppsala with offices in Italy and the US, Q-linea markets CE-IVD marked and FDA 510(k)-cleared ASTar instruments and consumables through a global partner network.
Average Trading Volume: 10,952
Technical Sentiment Signal: Sell
Current Market Cap: SEK398M
See more data about QLINEA stock on TipRanks’ Stock Analysis page.